그런데 주가는 오히려 떨어지네요… 왜 이런거죠?

ATryn(R) (Antithrombin [Recombinant]) Approved by the FDA

Feb 6, 2009 12:34:00 (ET)

FRAMINGHAM, Mass. & DEERFIELD, Ill., Feb 06, 2009 (BUSINESS WIRE) — GTC Biotherapeutics (GTCB, Trade ) and OVATION Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved ATryn(R) (Antithrombin [Recombinant]) for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients. It is not indicated for treatment of thromboembolic events in hereditary antithrombin deficient patients. ATryn is the first ever transgenically produced therapeutic protein and the first recombinant antithrombin approved in the U.S. Along with the approval of ATryn, the FDA’s Center for Veterinary Medicine also approved GTC’s New Animal Drug Application, the first of its kind to regulate genetically engineered animals. This is now required for a recombinant technology used to develop transgenic animals, such as the goats that produce recombinant antithrombin. GTC has granted OVATION the right to market ATryn in the U.S. and pursue further clinical development. The companies expect ATryn to be available in the second quarter of 2009.

A classic example of “Buy on the rumor, sell on the news”.

원래 FDA승인 나기전까지 계속 오르다가, 승인되면 profit taking이 일어납니다. 바이오주식은 이런 현상이 상당히 심합니다. 바이오 주식은 해보신 경험 없으시면 사지 마세요.